Next Article in Journal
In Search of a Unifying Concept in Human Diseases
Previous Article in Journal
Overview of Helicobacter pylori Infection: Clinical Features, Treatment, and Nutritional Aspects
Previous Article in Special Issue
Potential Effects of Melatonin and Micronutrients on Mitochondrial Dysfunction during a Cytokine Storm Typical of Oxidative/Inflammatory Diseases
Review

Empowering Melatonin Therapeutics with Drosophila Models

1
Biology Department, Concordia University, Montreal, QC H4B 1R6, Canada
2
Department of Biology, Coastal Carolina University, Conway, SC 29528-6054, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Alejandro Romero Martínez, Russel J. Reiter and Germaine Escames
Received: 1 August 2021 / Revised: 14 September 2021 / Accepted: 22 September 2021 / Published: 26 September 2021
(This article belongs to the Special Issue Novel Melatonin Based Therapies)
Melatonin functions as a central regulator of cell and organismal function as well as a neurohormone involved in several processes, e.g., the regulation of the circadian rhythm, sleep, aging, oxidative response, and more. As such, it holds immense pharmacological potential. Receptor-mediated melatonin function mainly occurs through MT1 and MT2, conserved amongst mammals. Other melatonin-binding proteins exist. Non-receptor-mediated activities involve regulating the mitochondrial function and antioxidant cascade, which are frequently affected by normal aging as well as disease. Several pathologies display diseased or dysfunctional mitochondria, suggesting melatonin may be used therapeutically. Drosophila models have extensively been employed to study disease pathogenesis and discover new drugs. Here, we review the multiple functions of melatonin through the lens of functional conservation and model organism research to empower potential melatonin therapeutics to treat neurodegenerative and renal diseases. View Full-Text
Keywords: melatonin; oxidative stress; Drosophila; longevity; PKD; neurodegeneration melatonin; oxidative stress; Drosophila; longevity; PKD; neurodegeneration
Show Figures

Figure 1

MDPI and ACS Style

Millet-Boureima, C.; Ennis, C.C.; Jamison, J.; McSweeney, S.; Park, A.; Gamberi, C. Empowering Melatonin Therapeutics with Drosophila Models. Diseases 2021, 9, 67. https://0-doi-org.brum.beds.ac.uk/10.3390/diseases9040067

AMA Style

Millet-Boureima C, Ennis CC, Jamison J, McSweeney S, Park A, Gamberi C. Empowering Melatonin Therapeutics with Drosophila Models. Diseases. 2021; 9(4):67. https://0-doi-org.brum.beds.ac.uk/10.3390/diseases9040067

Chicago/Turabian Style

Millet-Boureima, Cassandra, Caroline C. Ennis, Jurnee Jamison, Shana McSweeney, Anna Park, and Chiara Gamberi. 2021. "Empowering Melatonin Therapeutics with Drosophila Models" Diseases 9, no. 4: 67. https://0-doi-org.brum.beds.ac.uk/10.3390/diseases9040067

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop